NO20015757L - Felles salt av amlopidin og atorvastatin - Google Patents

Felles salt av amlopidin og atorvastatin

Info

Publication number: NO20015757L
Authority: NO; Norway
Prior art keywords: amlopidine; atorvastatin; common salt; salt; common
Prior art date: 1999-05-27

Application number

NO20015757A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015757D0 (no

Inventor

George Chang

Ernest Seiichi Hamanaka

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-27

Filing date

2001-11-26

Publication date

2001-12-20

2001-11-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2001-11-26 Publication of NO20015757D0 publication Critical patent/NO20015757D0/no

2001-12-20 Publication of NO20015757L publication Critical patent/NO20015757L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20015757A 1999-05-27 2001-11-26 Felles salt av amlopidin og atorvastatin NO20015757L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13626999P	1999-05-27	1999-05-27
PCT/IB2000/000590 WO2000073271A1 (fr)	1999-05-27	2000-05-08	Sel commun d'amlodipine et d'atorvastatine

Publications (2)

Publication Number	Publication Date
NO20015757D0 NO20015757D0 (no)	2001-11-26
NO20015757L true NO20015757L (no)	2001-12-20

Family

ID=22472108

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015757A NO20015757L (no)	1999-05-27	2001-11-26	Felles salt av amlopidin og atorvastatin

Country Status (36)

Country	Link
US (1)	US6262092B1 (fr)
EP (1)	EP1180097B1 (fr)
JP (1)	JP2003500473A (fr)
KR (1)	KR20020019450A (fr)
CN (1)	CN1373753A (fr)
AP (1)	AP2001002347A0 (fr)
AR (1)	AR028994A1 (fr)
AT (1)	ATE367376T1 (fr)
AU (1)	AU4138200A (fr)
BG (1)	BG106128A (fr)
BR (1)	BR0011008A (fr)
CA (1)	CA2375225C (fr)
DE (1)	DE60035581T2 (fr)
EA (1)	EA200101132A1 (fr)
EE (1)	EE200100632A (fr)
ES (1)	ES2287009T3 (fr)
GT (1)	GT200000077A (fr)
HN (1)	HN2000000050A (fr)
HR (1)	HRP20010857A2 (fr)
HU (1)	HUP0202070A3 (fr)
IL (1)	IL145837A0 (fr)
IS (1)	IS6133A (fr)
MA (1)	MA26739A1 (fr)
MX (1)	MXPA01012126A (fr)
NO (1)	NO20015757L (fr)
OA (1)	OA11951A (fr)
PA (1)	PA8494501A1 (fr)
PE (1)	PE20010168A1 (fr)
PL (1)	PL352828A1 (fr)
SK (1)	SK16802001A3 (fr)
TN (1)	TNSN00110A1 (fr)
TR (1)	TR200103411T2 (fr)
UA (1)	UA56363C2 (fr)
UY (1)	UY26163A1 (fr)
WO (1)	WO2000073271A1 (fr)
ZA (1)	ZA200109693B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
US20050119270A1 (en) *	2000-08-04	2005-06-02	Mason R. P.	Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US6835742B2 (en) *	2000-08-04	2004-12-28	R. Preston Mason	Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
GB0027410D0 (en) *	2000-11-09	2000-12-27	Pfizer Ltd	Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en)	2000-11-09	2004-05-18	Pfizer, Inc.	Mutual prodrug of amlodipine and atorvastatin
US20030114497A1 (en) *	2001-07-31	2003-06-19	Laman Alani	Pharmaceutical compositions of amlodipine and atorvastatin
DE10140421A1 (de) *	2001-08-17	2003-03-06	Bayer Ag	Neue Kombination
US6680334B2 (en)	2001-08-28	2004-01-20	Pfizer Inc	Crystalline material
AU2002363087A1 (en) *	2001-10-18	2003-05-06	Novartis Ag	Salts formed of an at1-receptor antagonist and a cardiovascular agent
CN1152013C (zh) *	2001-11-22	2004-06-02	张喜田	一类左旋氨氯地平盐的水合物及其制剂
US7670612B2 (en)	2002-04-10	2010-03-02	Innercap Technologies, Inc.	Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6699892B2 (en)	2002-06-04	2004-03-02	Yung Shin Pharmaceutical Industrial Co., Ltd.	Pharmaceutically acceptable salt of amlodipine and method of preparing the same
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
KR100462304B1 (ko) *	2002-07-30	2004-12-17	씨제이 주식회사	암로디핀의 유기산염
KR100496436B1 (ko) *	2002-07-30	2005-06-20	씨제이 주식회사	암로디핀의 유기산염
WO2005097191A2 (fr) *	2004-04-04	2005-10-20	Sepracor Inc.	Combinaisons comprenant de la (s)-amlodipine et un inhibiteur de la hmg-coa reductase ou un inhibiteur de l'absorption de cholesterol ou les deux a la fois et methodes permettant de reduire l'hypertension
CA2499047A1 (fr) *	2005-03-01	2006-09-01	Apotex Pharmachem Inc.	Methode de synthese d'un sel de semi-calcium d'atorvastatine
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP2081554A2 (fr) *	2006-09-27	2009-07-29	Dr. Reddy's Laboratories Ltd.	Compositions pharmaceutiques d'atorvastatine
GB0624087D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril combination salt
US20090042849A1 (en) *	2006-12-06	2009-02-12	Yochai Birnbaum	Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
JP2018516624A (ja) *	2015-04-15	2018-06-28	コンシーヴァルブエルエルシー	自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN105012258B (zh) *	2015-08-06	2017-11-03	北京嘉林药业股份有限公司	阿托伐他汀钙和氨氯地平片剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK161312C (da)	1982-03-11	1991-12-09	Pfizer	Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en)	1991-01-14	1992-10-13	Pfizer Inc	Method for treating congestive heart failure
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.

2000
- 2000-04-12 HN HN2000000050A patent/HN2000000050A/es unknown
- 2000-04-25 PA PA20008494501A patent/PA8494501A1/es unknown
- 2000-05-08 AP APAP/P/2001/002347A patent/AP2001002347A0/en unknown
- 2000-05-08 AT AT00920978T patent/ATE367376T1/de not_active IP Right Cessation
- 2000-05-08 SK SK1680-2001A patent/SK16802001A3/sk unknown
- 2000-05-08 BR BR0011008-6A patent/BR0011008A/pt not_active Application Discontinuation
- 2000-05-08 PL PL00352828A patent/PL352828A1/xx not_active Application Discontinuation
- 2000-05-08 EA EA200101132A patent/EA200101132A1/ru unknown
- 2000-05-08 OA OA1200100313A patent/OA11951A/en unknown
- 2000-05-08 MX MXPA01012126A patent/MXPA01012126A/es active IP Right Grant
- 2000-05-08 HR HR20010857A patent/HRP20010857A2/hr not_active Application Discontinuation
- 2000-05-08 HU HU0202070A patent/HUP0202070A3/hu unknown
- 2000-05-08 KR KR1020017015184A patent/KR20020019450A/ko not_active Ceased
- 2000-05-08 CN CN00808121A patent/CN1373753A/zh active Pending
- 2000-05-08 JP JP2000621338A patent/JP2003500473A/ja active Pending
- 2000-05-08 TR TR2001/03411T patent/TR200103411T2/xx unknown
- 2000-05-08 ES ES00920978T patent/ES2287009T3/es not_active Expired - Lifetime
- 2000-05-08 AU AU41382/00A patent/AU4138200A/en not_active Abandoned
- 2000-05-08 EE EEP200100632A patent/EE200100632A/xx unknown
- 2000-05-08 DE DE60035581T patent/DE60035581T2/de not_active Expired - Fee Related
- 2000-05-08 CA CA002375225A patent/CA2375225C/fr not_active Expired - Fee Related
- 2000-05-08 EP EP00920978A patent/EP1180097B1/fr not_active Expired - Lifetime
- 2000-05-08 IL IL14583700A patent/IL145837A0/xx unknown
- 2000-05-08 WO PCT/IB2000/000590 patent/WO2000073271A1/fr not_active Ceased
- 2000-05-24 MA MA25989A patent/MA26739A1/fr unknown
- 2000-05-24 US US09/578,204 patent/US6262092B1/en not_active Expired - Fee Related
- 2000-05-24 TN TNTNSN00110A patent/TNSN00110A1/fr unknown
- 2000-05-25 UY UY26163A patent/UY26163A1/es not_active Application Discontinuation
- 2000-05-25 PE PE2000000499A patent/PE20010168A1/es not_active Application Discontinuation
- 2000-05-25 GT GT200000077A patent/GT200000077A/es unknown
- 2000-05-26 AR ARP000102584A patent/AR028994A1/es not_active Application Discontinuation
- 2000-08-05 UA UA2001118092A patent/UA56363C2/uk unknown
2001
- 2001-10-30 IS IS6133A patent/IS6133A/is unknown
- 2001-11-21 BG BG106128A patent/BG106128A/xx unknown
- 2001-11-26 NO NO20015757A patent/NO20015757L/no not_active Application Discontinuation
- 2001-11-26 ZA ZA200109693A patent/ZA200109693B/en unknown

Also Published As

Publication number	Publication date
ATE367376T1 (de)	2007-08-15
HUP0202070A2 (en)	2002-10-28
DE60035581T2 (de)	2008-04-17
EP1180097B1 (fr)	2007-07-18
HRP20010857A2 (en)	2003-02-28
HN2000000050A (es)	2001-02-02
ES2287009T3 (es)	2007-12-16
OA11951A (en)	2006-04-13
EA200101132A1 (ru)	2002-04-25
US6262092B1 (en)	2001-07-17
HUP0202070A3 (en)	2003-03-28
AR028994A1 (es)	2003-06-04
CN1373753A (zh)	2002-10-09
BR0011008A (pt)	2002-02-19
GT200000077A (es)	2001-11-16
NO20015757D0 (no)	2001-11-26
TNSN00110A1 (fr)	2005-11-10
CA2375225C (fr)	2007-02-20
IL145837A0 (en)	2002-07-25
MA26739A1 (fr)	2004-12-20
AP2001002347A0 (en)	2001-12-31
JP2003500473A (ja)	2003-01-07
UY26163A1 (es)	2000-12-29
PL352828A1 (en)	2003-09-08
EP1180097A1 (fr)	2002-02-20
BG106128A (en)	2002-05-31
PA8494501A1 (es)	2002-07-30
AU4138200A (en)	2000-12-18
CA2375225A1 (fr)	2000-12-07
UA56363C2 (uk)	2003-05-15
DE60035581D1 (de)	2007-08-30
TR200103411T2 (tr)	2002-04-22
EE200100632A (et)	2003-02-17
PE20010168A1 (es)	2001-02-10
MXPA01012126A (es)	2002-06-04
WO2000073271A1 (fr)	2000-12-07
ZA200109693B (en)	2002-11-26
KR20020019450A (ko)	2002-03-12
IS6133A (is)	2001-10-30
SK16802001A3 (sk)	2003-02-04

Publication	Publication Date	Title
NO20015757L (no)	2001-12-20	Felles salt av amlopidin og atorvastatin
NO20030725D0 (no)	2003-02-14	Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
NO20015888L (no)	2002-01-31	Implanterbart gelpreparat og fremgangsmåter for fremstilling derav
NO20014046D0 (no)	2001-08-20	Gabapentinderivater for forhindring og behandling av visceral smerte
NO20022656D0 (no)	2002-06-05	Caspaseinhibitorer og anvendelse derav
ATE277615T1 (de)	2004-10-15	Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
NO20015773D0 (no)	2001-11-27	Forhindring og behandling av amyloidogen sykdom
DK1400518T3 (da)	2007-03-26	Heterocycliske forbindelser og lægemidler
NO20021401D0 (no)	2002-03-20	Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
NO20000996D0 (no)	2000-02-28	Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel
NO20040469L (no)	2004-04-30	Heterocykliske forbindelser samt fremstilling og anvendelse derav
IS7089A (is)	2003-12-22	Lyfjasamsetningar amlódipíns og atórvastatíns
NO20015274L (no)	2001-12-28	ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20015542D0 (no)	2001-11-13	Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20014314L (no)	2001-10-11	Blandinger og metoder for behandling av stafylokokkisk infeksjon
ATE268764T1 (de)	2004-06-15	Gegenseitige prodrugs von amlopidin und atorvastatin
NO20010487D0 (no)	2001-01-29	Disubstituert maleimidforbindelse og farmasöytisk anvendelse herav
PT1178981E (pt)	2003-11-28	3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DK1228026T3 (da)	2004-04-05	15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
PT1392670E (pt)	2005-10-31	Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
IS6118A (is)	2001-10-19	Samvirk áhrif amlódípíns og atórvastatíns
NO20013464D0 (no)	2001-07-12	Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
NO20022990L (no)	2002-08-20	Fremgangsmåte og sammensetning for behandling av smerte
IS4993A (is)	1999-12-10	Efnasamband og notkun thess

Legal Events

Date	Code	Title	Description
2004-01-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application